問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



MacKay Memorial Hospital

Link to Hospital │ Link to Clinical Trial Center

  • 0

    Total Beds

  • 0

    Total Doctors

  • mmhcto@gmail.com
  • Alice Huang
  • 25433535-2851
  • 104Taipei CityJhong ShanNo. 92, Sec. 2, Zhongshan N. Rd., Taipei City 10449, Taiwan

Recruiting Trial

201Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

566Cases

2015-08-15 - 2018-03-28

Phase III

A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Therapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

  • Condition/Disease

    Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

  • Test Drug

    MEDI4736

Participate Sites
5Sites

Terminated5Sites

王宏銘
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2010-07-01 - 2011-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2014-01-01 - 2020-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2002-04-01 - 2015-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2012-01-01 - 2015-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2014-02-01 - 2016-01-30

Others

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2012-05-15 - 2014-04-14

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2014-03-01 - 2015-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2018-07-01 - 2020-06-30

Phase III

A Randomized Controlled, Open Label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment

  • Condition/Disease

    Pancreatic Cancer

  • Test Drug

    EndoTAG-1

Participate Sites
12Sites

Terminated11Sites

白禮源
China Medical University Hospital-Taipei

未分科

陳仁熙
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2020-06-30 - 2023-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

1 42 43 44 45 46 57
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB